Keuangan Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ · Healthcare · Biotechnology · Karyawan: 975 · CEO: Frederick G. Vogt
- Harga
- $8,48 -11,30%
- Kapitalisasi pasar
- $3,84 M
- Nilai perusahaan
- $3,78 M
- Laporan terakhir
- Q2 '26 diajukan 2026-08-06
- Laporan berikutnya
- 2026-11-05 Estimasi EPS: -$0,08
Pendapatan (TTM)$325 jt+34,5% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)-91,1%+78,9 poin vs tahun laluLaba operasional: -$296 jt
Laba bersih (TTM)-$290 jt+25,7% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)-$296 jt+8,4% vs tahun laluCapex: $32,2 jt
EPS dilusian (TTM)-$0,73+40,7% vs tahun laluJumlah 4 kuartal terakhir
Kas neto$252 jt+1,5% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $3,84 M EV $3,78 M
- Pendapatan
- $325 jt 12 bulan terakhir
- Pertumbuhan pendapatan
- +57% Konsensus FY2026
- Margin laba
- -89,1% Laba bersih / pendapatan, TTM
- P/E
- -11,6× Forward -19,1× (FY2026)
- P/S
- 11,8× Harga / penjualan, TTM
- EV / EBITDA
- -15,0× TTM
- Arus kas bebas
- -$296 jt 12 bulan terakhir
- Laba bersih
- -$290 jt 12 bulan terakhir
- Estimasi pendapatan
- $415 jt Konsensus FY2026
- Laba
- 2026-11-05 Estimasi pendapatan: $116 jt
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-08-06): pendapatan melampaui 13,1%, EPS melampaui 17,6%Pendapatan $99,3 jt vs $87,8 jt yang diharapkan (+13,1%); EPS -$0,11 vs -$0,13 (+17,6%).
- Pertumbuhan pendapatan menguat: 65,7% yoyPendapatan Q2 '26: $99,3 jt, rata-rata empat kuartal sebelumnya: 42,6%.
- Margin operasional -91,1% (TTM), dibanding tahun lalu: +78,9 poinLaba operasional tumbuh 27,9%, pendapatan tumbuh 34,5%.
- Capex: 9,9% dari pendapatan (tahun lalu 8,3%)$32,2 jt diinvestasikan dalam 4 kuartal terakhir (+60,0% dibanding tahun sebelumnya). Arus kas bebas: -$296 jt.
- Jumlah saham dilusian naik dalam setahun: 34,6%Saham dilusian pada Q2 '26: 450 jt, setahun sebelumnya: 335 jt.
- Kas neto: $252 jtKas + investasi jangka pendek: $298 jt, utang termasuk sewa: $46 jt; tahun lalu kas neto: $248 jt.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $99,3 jt | $60 jt | +65,7% |
| Margin kotor | 56,1% | 18,5% | +37,6 poin |
| Laba operasional | -$51,9 jt | -$114 jt | +54,4% |
| Margin operasional | -52,3% | -189,8% | +137,5 poin |
| Laba bersih | -$47,3 jt | -$112 jt | +57,6% |
| EPS dilusian | -$0,11 | -$0,33 | +66,7% |
| Arus kas operasional | -$60,8 jt | -$67,4 jt | +9,8% |
| Capex | $5,44 jt | $7,46 jt | -27,1% |
| Arus kas bebas | -$66,3 jt | -$74,9 jt | +11,5% |
| R&D | $58,9 jt | $77,9 jt | -24,5% |
| Kompensasi berbasis saham | $11,7 jt | $14,9 jt | -21,5% |
Dilaporkan vs konsensus
2026-08-06| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $99,3 jt | $87,8 jt | +13,1% |
| EPS (basis konsensus) | -$0,11 | -$0,13 | +17,6% |
Dari laporan 2026-08-06 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q3 '23 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Product | $500 rb | – | 100,0% | – | – |
Pendapatan per wilayah
porsi dari total| Segmen | Q3 '23 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $99 jt | +68,9% | 99,7% | $321 jt | +19,8% | |
| Non-US | $346 rb | -74,3% | 0,3% | $3,64 jt | -18,7% |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- -$264 jt
- Capex
- -$32,2 jt
- Buyback
- $0
- Dividen
- $0
- Akuisisi
- $0
- Utang neto diterbitkan
- $0
- Kompensasi berbasis saham
- $46,7 jt
- Arus kas bebas
- -$296 jt
- Dikembalikan ke pemegang saham / FCF
- 0,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -11,6× | – | – |
| EV / EBITDA | -15,0× | – | – |
| EV / Penjualan | 11,6× | 530,3× 3 dari 5 tahun | 3,3× – 1.574,9× |
| Harga / FCF | -13,0× | – | – |
| Harga / Nilai buku | 5,2× | 2,9× | 1,4× – 4,7× |
| Imbal hasil FCF | -7,7% | -22,3% | -34,5% – -9,1% |
| Imbal hasil modal yang diinvestasikan | -36,0% | -57,0% | -68,2% – -49,0% |
| Imbal hasil ekuitas | -40,5% | -63,7% | -79,2% – -52,4% |
Analis
Target konsensus $13,44 (+58,5%)
rentang $5,00 – $20,00 · peringkat Buy
Beli kuat0
Beli15
Tahan6
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $415 jt | +57,4% | -$0,44 | +59,3% | -19,1× | 6 |
| FY2027 | $594 jt | +43,1% | -$0,17 | +61,7% | -49,9× | 6 |
| FY2028 | $882 jt | +48,5% | $0,24 | +241,7% | 35,2× | 4 |
| FY2029 | $1,11 M | +26,0% | $0,27 | +10,0% | 32,0× | 1 |
| FY2030 | $1,42 M | +27,6% | $0,52 | +96,2% | 16,3× | 1 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 179 angka yang ditandai Iovance Biotherapeutics, Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $26,2 jt | $32 jt | -18,1% | $22,2 jt | $27,5 jt | -19,4% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $102 jt | $59,9 jt | +70,4% | $82,4 jt | $69,3 jt | +18,9% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $1,41 jt | $2 jt | -29,5% | $7,2 jt | $10,3 jt | -29,8% |
| Accrued Employee Benefits, Current | $30,7 jt | $24,3 jt | +26,3% | $33,8 jt | $31,9 jt | +5,9% |
| Accrued Liabilities and Other Liabilities | $78 jt | $89,1 jt | -12,5% | $111 jt | $81,9 jt | +35,7% |
| Accrued Liabilities, Current | $78 jt | $89,1 jt | -12,5% | $111 jt | $81,9 jt | +35,7% |
| Accrued Professional Fees, Current | $1,54 jt | $2,04 jt | -24,6% | $1,42 jt | $2,47 jt | -42,6% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $56,4 jt | $42,1 jt | +33,9% | $48,8 jt | $36 jt | +35,4% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $13,1 jt | $20,9 jt | -37,3% | $16,4 jt | -$1,05 jt | +1.671,7% |
| Additional Paid in Capital | $3,62 M | $3,29 M | +10,2% | $3,46 M | $3,1 M | +11,7% |
| Amortization of Intangible Assets | $5,72 jt | $5,7 jt | +0,3% | $23,1 jt | $26,4 jt | -12,5% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | -1,39 jt | -349 rb | -299,5% | 29,7 jt | 30,9 jt | -4,1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $11,9 jt | $14,5 jt | -17,9% | $60,9 jt | $111 jt | -45,1% |
| Assets | $916 jt | $907 jt | +0,9% | $913 jt | $910 jt | +0,3% |
| Assets, Current | $464 jt | $423 jt | +9,9% | $443 jt | $457 jt | -3,1% |
| Cash and Cash Equivalents, at Carrying Value | $111 jt | $132 jt | -16,4% | $163 jt | $116 jt | +41,0% |
| Cash Equivalents, at Carrying Value | $61,1 jt | $81,4 jt | -24,9% | $60,5 jt | $61,4 jt | -1,6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $117 jt | $138 jt | -15,6% | $169 jt | $122 jt | +38,5% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$85,7 jt | -$39,6 jt | -116,3% | $47 jt | -$59,3 jt | +179,3% |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 650 jt | 500 jt | +30,0% | 500 jt | 500 jt | 0,0% |
| Common Stock, Shares, Issued | 453 jt | 342 jt | +32,5% | 412 jt | 305 jt | +35,0% |
| Common Stock, Shares, Outstanding | 453 jt | 342 jt | +32,5% | 412 jt | 305 jt | +35,0% |
| Common Stock, Value, Issued | $19 rb | $14 rb | +35,7% | $17 rb | $13 rb | +30,8% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$46,9 jt | -$97,1 jt | +51,7% | -$373 jt | -$376 jt | +0,6% |
| Conversion of Stock, Amount Converted | $02025-12-31 | – | – | $1 rb | – | – |
| Cost of Revenue | $43,6 jt | $48,9 jt | -10,8% | $173 jt | $93,2 jt | +85,7% |
| Costs and Expenses | $151 jt | $174 jt | -13,0% | $667 jt | $559 jt | +19,2% |
| Debt Securities, Available-for-sale | $248 jt | $250 jt | -0,8% | $194 jt | $270 jt | -27,9% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $1 rb2026-03-31 | $7 rb | -85,7% | $63 rb | $117 rb | -46,2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $74 rb | $24 rb | +208,3% | $910 rb2022-12-31 | $612 rb | +48,7% |
| Debt Securities, Available-for-sale, Amortized Cost | $248 jt | $250 jt | -0,8% | $194 jt | $269 jt | -27,9% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | 0,0% | 0,0% | – | – | – | – |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | 0 item2025-12-31 | – | – | 0 item | – | – |
| Debt Securities, Available-for-sale, Current | $187 jt | $169 jt | +10,8% | $134 jt | $208 jt | -35,7% |
| Debt Securities, Available-for-sale, Unrealized Loss | $0 | $0 | – | $0 | $0 | – |
| Deferred Income Tax Expense (Benefit) | -$1,37 jt | $1,99 jt | -169,1% | -$2,07 jt | -$2,83 jt | +26,8% |
| Deferred Income Tax Liabilities, Net | $29,3 jt | $34,7 jt | -15,5% | $31,8 jt | $32,3 jt | -1,5% |
| Deferred Tax Assets, Gross | $706 jt2025-12-31 | $575 jt | +23,0% | $706 jt | $575 jt | +23,0% |
| Deferred Tax Assets, Net of Valuation Allowance | $19 jt2025-12-31 | $16,9 jt | +12,1% | $19 jt | $16,9 jt | +12,1% |
| Deferred Tax Assets, Operating Loss Carryforwards | $416 jt2025-12-31 | $303 jt | +37,4% | $416 jt | $303 jt | +37,4% |
| Deferred Tax Assets, Other | $2,22 jt2025-12-31 | $0 | – | $2,22 jt | $0 | – |
| Deferred Tax Assets, Tax Credit Carryforwards | $65,2 jt2025-12-31 | $66,9 jt | -2,5% | $65,2 jt | $66,9 jt | -2,5% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $41,3 jt2025-12-31 | $40,9 jt | +0,9% | $41,3 jt | $40,9 jt | +0,9% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | $18,9 jt2025-12-31 | $11,5 jt | +64,2% | $18,9 jt | $11,5 jt | +64,2% |
| Deferred Tax Assets, Valuation Allowance | $688 jt2025-12-31 | $558 jt | +23,3% | $688 jt | $558 jt | +23,3% |
| Deferred Tax Liabilities, Net | $31,8 jt2025-12-31 | $32,3 jt | -1,5% | $31,8 jt | $32,3 jt | -1,5% |
| Deferred Tax Liabilities, Other | $179 rb2025-12-31 | $0 | – | $179 rb | $0 | – |
| Defined Contribution Plan, Cost | – | – | – | $6,4 jt | $4,7 jt | +36,2% |
| Depreciation, Depletion and Amortization | $3,78 jt | $3,4 jt | +11,3% | $12,9 jt | $11,3 jt | +14,3% |
| Depreciation, Depletion and Amortization, Nonproduction | $9,5 jt | $9,35 jt | +1,6% | $35,9 jt | $37,6 jt | -4,4% |
| Earnings Per Share, Basic | -$0,11 | -$0,33 | +66,7% | -$1,09 | -$1,28 | +14,8% |
| Earnings Per Share, Diluted | -$0,11 | -$0,33 | +66,7% | -$1,09 | -$1,28 | +14,8% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | -$124 rb | $739 rb | -116,8% | $1,14 jt | -$541 rb | +311,5% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$82,5 jt | – | – |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 0,0% | 0,0% | – | 21,0% | 21,0% | 0,0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | – | – | – | $58,5 jt | – | – |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | – | – | – | -15,0% | -29,0% | +48,3% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | – | – | – | $1,78 jt | – | – |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | – | – | – | 0,0% | – | – |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-02